Healthcare industry renews pressure on FDA to address DEHP concerns
This article was originally published in Clinica
Executive Summary
At the time of going to press, the US Food and Drug Administration had not responded to the request submitted by a consortium of healthcare providers and a public interest group over a month ago, asking for a new labelling regulation that specifically targets medical devices that may leach potentially dangerous chemicals into the bloodstream.
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.